Eucure Biopharma announced that it has entered into a collaborative agreement with ISU ABXIS Co., Ltd. Under the terms of the agreement, ISU ABXIS will utilize the sequence of YH003, Biocytogen's humanized agonistic anti-CD40 antibody currently in phase II clinical trials, to construct a few groups of tri-specific antibodies and develop cancer drugs for multiple indications using its technology platform. Eucure Biopharma will receive an upfront payment, milestone payments and royalties.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
6,610 KRW | -0.30% | -6.51% | +9.26% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9.26% | 172M | |
-2.95% | 90.75B | |
-1.97% | 39.03B | |
-15.47% | 31.85B | |
+60.52% | 26.26B | |
-22.81% | 14.13B | |
-8.82% | 12.87B | |
-11.77% | 11.6B | |
-45.97% | 10.91B | |
+3.15% | 8.89B |
- Stock Market
- Equities
- A086890 Stock
- News ISU Abxis Co., Ltd.
- Eucure Biopharma Announces Partnership with ISU ABXIS for the Development of Tri-specific Antibodies using YH003 Antibody Sequence